July 16, 2026 |
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they examine the evolving role of congresses, from experience design and technology to strategy, measurement and commercial impact.

Simon Davenport, Global Head of Environments at Inizio Engage, explores the characteristics that set the most successful congress experiences apart. Drawing on observations from the exhibition floor, the article highlights three key principles: creating a clear and consistent scientific narrative, designing interactions that genuinely enhance engagement rather than relying on technology for its own sake, and building flexible experiences that allow HCPs to engage at different levels. The article explains why thoughtful experience design is becoming increasingly important as congress environments grow more competitive.
Read full article here.
Nick Bellomo, VP of Experience and Technology at Inizio Medical, examines the technology and engagement innovations that stood out across ASCO® 2026. From immersive LED environments and AI-powered interactions to tactile, low-tech activations, the article explores how organisations are rethinking the use of technology to create more meaningful scientific engagement. It concludes that the most effective congress experiences combine creativity with purposeful design to strengthen scientific communication and generate valuable behavioural insights.
Read full article here.
Lynsey Holbrook, Global Client Development Director at Inizio Engage, focuses on the growing complexity of congress planning and the challenge of demonstrating return on investment. The article explores why many pharmaceutical organisations struggle to connect strategy, execution and measurement, despite increasing investment in congresses. It outlines how a more connected approach can help teams align stakeholders, create more coordinated delegate experiences and measure the activities that drive meaningful scientific and commercial outcomes.
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
Evolution from man to machine
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio…
Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines….
Organising a company’s presence, not just logistically, but in terms of delivering key information, data and messages, is a massive part of some people’s workload at this time of year….
Two clients were co-developing a product and needed to understand the patient journey in two areas of oncology, in order to identify the leverage points where they could provide an…
What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets?
As part of our continued growth, we are delighted to announce a new intake of 17 Research Analysts and 5 Fieldwork Project Coordinators into our annual market research graduate programme.http://www.researchpartnership.com/news/2016/09/new-graduates-2016/
With the imminent expected approval and launch of a new product, our client needed to conduct global tracking research to understand knowledge, perceptions, awareness and recall around their product and the quality…
The benefits of understanding the patient journey are well documented in mature markets. But in emerging markets the patient journey is less understood. We recently presented a webinar hosted by…
The IBD syndicated market tracker is part of our large auto-immune portfolio
